Hospital-acquired Bacterial Pneumonia
📧 Sign up to get email alerts when something new happens for Hospital-acquired Bacterial Pneumonia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex [Phase 2]
Phase 2 clinical trial evaluating safety and pharmacokinetics of OMN6 for hospital-acquired and ventilator-associated pneumonia due to Acine…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex [Phase 2]
Phase 2 clinical trial evaluating BV100 with low-dose polymyxin B plus either ceftazidime/avibactam or cefiderocol for carbapenem-resistant …
-
EMA approval · 2026-01-26EMA Authorised: Recarbrio (imipenem monohydrate;cilastatin sodium;relebactam monohydrate) — Merck Sharp & Dohme B.V.
EMA authorised Recarbrio (imipenem/cilastatin/relebactam) for use in Gram-negative bacterial infections, including hospital-acquired/ventila…
-
CLINICAL_TRIALS research · 2025-07-30Clinical Trial Update: Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections [Phase 3]
Phase 3 trial is recruiting to assess efficacy and safety of meropenem plus pralubactam for carbapenem-resistant Enterobacteriaceae infectio…
-
CLINICAL_TRIALS trial_result · 2025-05-25Clinical Trial Update: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants [Phase 2]
Phase 2 pediatric study of cefiderocol in hospitalized children evaluating safety, tolerability, and pharmacokinetics has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-04-22Clinical Trial Update: A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia [Phase 2]
A Phase 2 clinical trial of HRS-8427 for adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia is …
-
CLINICAL_TRIALS trial_result · 2023-02-01Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex [Phase 3]
Phase 3 study evaluating intravenous sulbactam-ETX2514 for infections caused by Acinetobacter baumannii-calcoaceticus complex has completed …
-
FDA approval · 2020-07-07FDA Approved: VIBATIV — Supplemental Application (Cumberland Pharmaceuticals Inc.)
FDA approved a supplemental application for VIBATIV (telavancin hydrochloride) submitted by Cumberland Pharmaceuticals Inc. The action updat…
-
CLINICAL_TRIALS withdrawal · 2019-01-11Clinical Trial Update: A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia [Phase 3]
Phase 3 trial comparing meropenem-vaborbactam to piperacillin/tazobactam for hospital-acquired and ventilator-associated bacterial pneumonia…
-
CLINICAL_TRIALS trial_result · 2018-12-11Clinical Trial Update: Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults [Phase 3]
Phase 3 trial comparing Vabomere to best available therapy in adults with serious infections; completed with results posted in 2018.
-
FDA label_change · 2015-09-02FDA Approved: AVYCAZ — Supplemental Application (Allergan, Inc.)
FDA supplemental application for Avycaz (ceftazidime/avibactam) submitted by Allergan to modify the product labeling.
-
FDA approval · 2014-03-13FDA Approved: VIBATIV — Supplemental Application (Cumberland Pharmaceuticals Inc.)
FDA approved a supplemental labeling application for VIBATIV (telavancin hydrochloride) submitted by Cumberland Pharmaceuticals. The approva…
-
FDA approval · 2013-12-12FDA Approved: VIBATIV — Supplemental Application (Cumberland Pharmaceuticals Inc.)
FDA approved a supplemental application for Vibativ (telavancin hydrochloride) from Cumberland Pharmaceuticals Inc.
-
FDA approval · 2009-09-11FDA Approved: VIBATIV — Original Application (Cumberland Pharmaceuticals Inc.)
FDA approved Vibativ (telavancin hydrochloride) through an original NDA for the treatment of hospital-acquired bacterial pneumonia and compl…